Terms: = Endocrine gland cancer AND KIF5B, ENSG00000170759, 3799, P33176, UKHC, KNS1, KNS, KINH
14 results:
1. Purification of time-resolved insulin granules reveals proteomic and lipidomic changes during granule aging.
Neukam M; Sala P; Brunner AD; Ganß K; Palladini A; Grzybek M; Topcheva O; Vasiljević J; Broichhagen J; Johnsson K; Kurth T; Mann M; Coskun Ü; Solimena M
Cell Rep; 2024 Mar; 43(3):113836. PubMed ID: 38421874
[TBL] [Abstract] [Full Text] [Related]
2. Identification of novel early pancreatic cancer biomarkers kif5b and SFRP2 from "first contact" interactions in the tumor microenvironment.
Charles Jacob HK; Signorelli R; Charles Richard JL; Kashuv T; Lavania S; Middleton A; Gomez BA; Ferrantella A; Amirian H; Tao J; Ergonul AB; Boone MM; Hadisurya M; Tao WA; Iliuk A; Kashyap MK; Garcia-Buitrago M; Dawra R; Saluja AK
J Exp Clin Cancer Res; 2022 Aug; 41(1):258. PubMed ID: 36002889
[TBL] [Abstract] [Full Text] [Related]
3. Associations between genetic variants of kif5b, FMN1, and MGAT3 in the cadherin pathway and pancreatic cancer risk.
Zhao L; Liu H; Luo S; Moorman PG; Walsh KM; Li W; Wei Q
Cancer Med; 2020 Dec; 9(24):9620-9631. PubMed ID: 33200553
[TBL] [Abstract] [Full Text] [Related]
4. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract] [Full Text] [Related]
5. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract] [Full Text] [Related]
6. Drug resistance profiles of mutations in the RET kinase domain.
Liu X; Shen T; Mooers BHM; Hilberg F; Wu J
Br J Pharmacol; 2018 Sep; 175(17):3504-3515. PubMed ID: 29908090
[TBL] [Abstract] [Full Text] [Related]
7. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract] [Full Text] [Related]
8. kif5b/RET Rearrangement in a Carcinoma of the Thyroid gland: A Case Report of a Fatal Disease.
Viola D; Giani C; Mazzeo S; Ugolini C; Ciampi R; Molinaro E; Agate L; Borrelli N; Chella A; Fontanini G; Basolo F; Elisei R
J Clin Endocrinol Metab; 2017 Sep; 102(9):3091-3096. PubMed ID: 28911147
[TBL] [Abstract] [Full Text] [Related]
9. Papillary thyroid microcarcinoma co-exists with Hashimoto's thyroiditis: Is strain elastography still useful?
Li Y; Wang Y; Wu Q; Hu B
Ultrasonics; 2016 May; 68():127-33. PubMed ID: 26945905
[TBL] [Abstract] [Full Text] [Related]
10. kif5b/RET fusion gene in surgically-treated adenocarcinoma of the lung.
Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
[TBL] [Abstract] [Full Text] [Related]
11. Estimating the relative risk of pancreatic cancer associated with exposure agents in job title data in a hierarchical Bayesian meta-analysis.
Ojajärvi A; Partanen T; Ahlbom A; Hakulinen T; Kauppinen T; Weiderpass E; Wesseling C
Scand J Work Environ Health; 2007 Oct; 33(5):325-35. PubMed ID: 17973058
[TBL] [Abstract] [Full Text] [Related]
12. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract] [Full Text] [Related]
13. Production of immunoreactive calcitonin and some other tumor markers by established human carcinoma cell lines.
Ichiki S; Kuroki M; Matsunaga A; Kuroki M; Matsuoka Y
Jpn J Cancer Res; 1986 Mar; 77(3):270-5. PubMed ID: 3084416
[TBL] [Abstract] [Full Text] [Related]
14. Identification and partial characterization of the unglycosylated peptide of carcinoembryonic antigen synthesized by human tumor cell lines in the presence of tunicamycin.
Kuroki M; Kuroki M; Ichiki S; Matsuoka Y
Mol Immunol; 1984 Aug; 21(8):743-6. PubMed ID: 6205259
[TBL] [Abstract] [Full Text] [Related]
